Search company, investor...

Satori Pharmaceuticals

Founded Year



Dead | Dead

Total Raised


About Satori Pharmaceuticals

Satori Pharmaceuticals is a developing therapeutics for Alzheimer's Disease (AD). The company is developing small molecule compounds that are orally active and designed for chronic dosing in seniors. The highly selective gamma secretase modulators reduce the production of amyloid beta 42, while sparing other gamma substrates. This selectivity and expected safety profile provide the opportunity for Satori's lead compounds to treat patients in early-stage disease, potentially slowing or stopping the disease, before major brain damage or onset of clinical symptoms.

Headquarters Location

281 Albany Street

Cambridge, Massachusetts, 02139,

United States


Missing: Satori Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Satori Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Satori Pharmaceuticals Patents

Satori Pharmaceuticals has filed 2 patents.

patents chart

Application Date

Grant Date


Related Topics




Alzheimer's disease, Transcription factors, Rare diseases, Proteins, Cognitive disorders


Application Date


Grant Date



Related Topics

Alzheimer's disease, Transcription factors, Rare diseases, Proteins, Cognitive disorders



Latest Satori Pharmaceuticals News

Concert, Alere, TremRx, & More Names from Boston Life Sciences News

Mar 2, 2012

XconomyBoston —  Acquisitions, licensing deals, and companies emerging from stealth mode made up the New England life sciences news this week. —My colleague Arlene took a closer look at the Alzheimer’s drugmaker Satori Pharmaceuticals, which last week scored a $15 million venture funding round . Cambridge, MA-based Satori is looking to an unusual source to develop Alzheimer’s drugs : the flowering herbaceous plant black cohosh, which is most commonly marketed as a nutritional supplement to relieve menopause symptoms such as hot flashes. —We reported on two big Boston-area acquisitions : Waltham, MA-based Alere’s $270 million-plus acquisition of the toxicology screening tech company eScreen, and Japan-based Dainippon Sumitomo Pharma’s acquisition of Boston Biomedical, a maker of drugs targeting cancer stem cells.

Satori Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Satori Pharmaceuticals founded?

    Satori Pharmaceuticals was founded in 2004.

  • Where is Satori Pharmaceuticals's headquarters?

    Satori Pharmaceuticals's headquarters is located at 281 Albany Street, Cambridge.

  • What is Satori Pharmaceuticals's latest funding round?

    Satori Pharmaceuticals's latest funding round is Dead.

  • How much did Satori Pharmaceuticals raise?

    Satori Pharmaceuticals raised a total of $47.5M.

  • Who are the investors of Satori Pharmaceuticals?

    Investors of Satori Pharmaceuticals include New Enterprise Associates, InterWest Partners, Prospect Venture Partners and Queensland BioCapital Funds.

  • Who are Satori Pharmaceuticals's competitors?

    Competitors of Satori Pharmaceuticals include Bellus Health, Humanetics, Annovis Bio, Intarcia Therapeutics, Synapsin Pharmaceuticals and 12 more.

Compare Satori Pharmaceuticals to Competitors


Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

NeoCytex BioPharma

NeoCytex BioPharmaceuticals develops therapeutics to promote the repair and rejuvenation of damaged tissues. The lead drug candidate NBI-18 is being developed for speeding up recovery from neurodegenerative (Parkinson's, Alzheimer's) and cerebrovascular diseases.

CoImmune Logo

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.


Osteologix develops pharmaceutical products for bone and cartilage disorders addressing large markets and offering low-risk development. The therapies developed by Osteologix represent valuable solutions to the patients suffering from diseases of bone and cartilage, and they represent cost-effective therapeutic options for the healthcare providers. Osteologix's lead compound for prophylaxis and treatment of osteoporosis is being developed for multiple clinical indications. The main program is aimed at osteoporosis. Additional programs are aimed at secondary indications in metabolic bone diseases and OA exploiting maximal synergies with the Osteoporosis program.

Valens Therapeutics

Valens Therapeutics is a pharmaceutical company focused on the development of therapeutic products for the treatment of neovascular diseases including certain pathological conditions in the eye and cancer. The company's initial focus is on ophthalmologic disorders caused by unregulated angiogenesis and which offer major opportunities for improved therapies. The ultimate goal is to offer a platform technology of multiple indications for both the ophthalmology and oncology markets. The company's business strategy also includes providing to scientists in the private, government and academic sectors full access to a GMP qualified cleanroom suite for the manufacturing of biologics

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.